Corbus Pharmaceuticals Announces FDA Clearance to Initiate TEMPO-1 Registrational Study of CRB-701 in Patients with 2L Oropharyngeal Cancer

Corbus Pharmaceuticals (CRBP) has received FDA clearance to initiate TEMPO-1, a registrational study for CRB-701, its next-generation Nectin-4 targeted antibody-drug conjugate (ADC) in second-line oropharyngeal squamous cell carcinoma. Enrollment is expected to begin in September 2026, marking a material progression from development into late-stage clinical validation.

The addressable patient population is substantial: second-line OPSCC represents approximately 50% of head and neck cancer cases in the 2L setting, with roughly 14,000 eligible patients annually in the U.S. This market size provides meaningful commercial upside if CRB-701 demonstrates efficacy, positioning the compound as a potentially significant revenue driver for the company's oncology pipeline.

From a competitive perspective, ADCs remain a high-growth oncology class with proven clinical benefits in solid tumors. Nectin-4 targeting has shown promise in urothelial and other cancers, suggesting mechanistic plausibility in OPSCC. TEMPO-1 initiation represents de-risking of the candidate and validates the regulatory pathway forward.

Sector implication: This announcement is favorable for the biotech and specialty pharmaceutical sector, particularly companies with clinical-stage oncology assets. The FDA clearance reinforces confidence in ADC platform viability and may elevate sentiment around early-stage oncology developers with comparable mechanisms of action.